Abstract
In this issue of Seminars, we have assembled an internationally renowned group of clinicians and scientists to discuss current controversies and evolving concepts in idiopathic pulmonary fibrosis (IPF). Over the past 5 years, the implementation of an improved classification system of the idiopathic interstitial pneumonias (IIPs) has helped to define subgroups of non-IPF patients who carry more favorable prognoses and are more likely to respond to currently available therapies.[1] IPF, the most common of the IIPs, remains enigmatic and no effective therapies currently exist. Our panel of experts outlines current concepts and controversies regarding pathogenesis, diagnosis, and management of patients with IPF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Seminars in Respiratory and Critical Care Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
